Fig 1.
Distribution of serotypes of cases included in the study according to the receipt of any dose of PCV13 vaccinea.
ONV = Other non-PCV13 serotypes aAny child who received only PCV7 or PCV10 was excluded
Table 1.
Characteristics of cases and controls.
Table 2.
Crude and adjusted effectiveness of the 13-valent pneumococcal conjugate vaccination against IPD caused by PCV13 serotypes including and excluding serotype 3 in the prevention of invasive pneumococcal disease in children aged 7–59 months according to vaccination schedule, number of doses received and age.
Table 3.
Crude and adjusted effectiveness of the 13-valent pneumococcal conjugate vaccination against IPD caused by PCV13-non-PCV7 serotypes including and excluding serotype 3 in children aged 7–59 months according to vaccination schedule, number of doses received and age.
Table 4.
Crude and adjusted effectiveness of the 13-valent pneumococcal conjugate vaccination against IPD in children aged 7–59 months by specific serotype, vaccination schedule, and number of doses received.